ライフサイエンスコーパス: tumor marker

1 Calcitonin is the principal serum tumor marker.

2 ion, and that NSP5alpha3alpha may serve as a tumor marker.

3 nducible protein (PIP), is a specific breast tumor marker.

4 The CRD-BP might be a novel human tumor marker.

5 cer development and may serve as a potential tumor marker.

6 nosensing of prostate-specific antigen (PSA) tumor marker.

7 lar endothelial growth factor (VEGF165) as a tumor marker.

8 he trend of TgAb measurements as a surrogate tumor marker.

9 protein product has been considered a useful tumor marker.

10 nosensor for detection of the serum level of tumor marker.

11 blood analysis and diagnosis based on cancer tumor markers.

12 linical utility of prognostic and predictive tumor markers.

13 ugh sensitive, is nonspecific for particular tumor markers.

14 chanistically to the overexpression of other tumor markers.

15 the basis of clinical presentation and serum tumor markers.

16 f Notch1 pathway proteins and neuroendocrine tumor markers.

17 iagnosis and patient perspectives on bladder tumor markers.

18 sting the potential value of these miRNAs as tumor markers.

19 ase, histologic type, and elevation of serum tumor markers.

20 re overexpressed in cancer and serve as good tumor markers.

21 in cancer and are potential drug targets and tumor markers.

22 ontrols, suggests that they are novel breast tumor markers.

23 or the identification of clinically relevant tumor markers.

24 noassays for peptides, including polypeptide tumor markers.

25 omas and the development of new and specific tumor markers.

26 analyses of SAGE databases to identify novel tumor markers.

27 vels to normalize the distributions of these tumor markers.

28 cilitating the rapid identification of novel tumor markers.

29 plastic tissues can, in turn, identify novel tumor markers.

30 ieved a durable partial response with normal tumor markers.

31 re, serine proteases are excellent candidate tumor markers.

32 five principal groups on the basis of three tumor markers.

33 d demographic factors associated with use of tumor markers.

34 rker levels while controlling for additional tumor markers.

35 serotype 5 and the other binding to various tumor markers.

36 ed antigens (TAAs) were shown to be relevant tumor markers.

37 l, dilation of the main pancreatic duct, and tumor markers.

38 mor-specific protein that may be useful as a tumor marker, a target for cytotoxin/immunotoxin, or alt

39 ing parameters, in conjunction with biologic tumor markers, a novel means of determining prognosis fo

40 s transcription of AFP, an oncodevelopmental tumor marker aberrantly reactivated in hepatoma cells.

41 at cooperate to effectively target mSin3A to tumor marker AFP and reestablish transcription repressio

42 easure the concentrations of seven important tumor markers: AFP, ferritin, CEA, hCG-beta, CA 15-3, CA

43 A subset of patients with elevated serum tumor markers after chemotherapy is curable with surgery

44 astatic germ cell cancer with elevated serum tumor markers after first-line (50 patients) or second-l

45 ificance of the rate of decline of the serum tumor marker alpha-fetoprotein (AFP) and human chorionic

46 gion (-850) and core promoter of the hepatic tumor marker alpha-fetoprotein (AFP) gene.

47 e and confer developmental repression of the tumor marker alpha-fetoprotein (AFP).

48 Serum tumor markers alpha-fetoprotein and human chorionic gona

49 ncluded physical examination, measurement of tumor markers (alpha fetoprotein and human chorionic gon

50 The tumor markers also decreased significantly after treatme

51 tissues, and may serve as the best candidate tumor markers among the seven genes studied.

52 These results support the use of PA28 as a tumor marker and a potential target for therapeutic inte

53 vely expressed red fluorescence protein as a tumor marker and green fluorescence protein (GFP) as a r

54 gen (PSA) is considered a uniquely important tumor marker and is broadly used for early detection of

55 onsiderable interest in Gpc3 as a diagnostic tumor marker and its possible role in tumorigenesis.

56 d secondary endpoints included radiological, tumor marker and pathological response to neoadjuvant th

57 UC1 has generated considerable interest as a tumor marker and potential target for tumor killing.

58 erous publications have addressed CD147 as a tumor marker and regulator of cytoskeleton, cell growth,

59 eceptor type alpha (FR-alpha) is a promising tumor marker and target.

60 agents, immune-based therapies, circulating tumor markers and antiangiogenic agents.

61 are derived from tumors because they express tumor markers and are decreased by tumor resection.

62 overall response determined by all imaging, tumor markers and clinical findings at serial follow up.

63 of baseline and follow-up liver function and tumor markers and computed tomographic or magnetic reson

64 indings and immunohistochemical staining for tumor markers and for cytokeratin and mucin proteins wer

65 owerful tool for the identification of novel tumor markers and for the characterization of genetic al

66 New tumor markers and genetic risk factors continue to be di

67 he current use and future potential of novel tumor markers and molecular analysis to characterize cys

68 a minimally invasive system for identifying tumor markers and monitoring drug therapy.

69 mptomatic cervical cancer patients with high tumor markers and negative conventional-imaging findings

70 ferentially expressed genes may be useful as tumor markers and prognostic indicators and may be suita

71 Surveillance included measurement of serum tumor markers and radiologic imaging at defined interval

72 CR was defined as normalization of serum tumor markers and resolution of radiographic disease (re

73 Serum tumor markers and surgery after chemotherapy have essent

74 ned NOS2 expression and its association with tumor markers and survival in 248 breast tumors.

75 agents, immune-based therapies, circulating tumor markers and targeting agents.

76 ethylation changes hold great promise as DNA tumor markers and their potentially reversible state cre

77 New tumor markers and therapeutic approaches are still neede

78 ing of PD-1, PD-L1, OX40, CD27, TIM3, CD3, a tumor marker, and DAPI.

79 plasma may be useful as a lymphoma-specific tumor marker, and failure to clear clonal Ig DNA may ide

80 inated LCDIO, green fluorescent protein as a tumor marker, and Hoechst 33258 dye as an intravital end

81 relapses were mainly detected by increase in tumor markers, and late relapses were detected by comput

82 Ts inside cells labeled with folate receptor tumor markers, and NIR-triggered cell death, without har

83 rtance of age, tumor site, stage, histology, tumor markers, and treatment regimen and estimate the pe

84 stage [American Joint Committee on Cancer], tumor markers, and treatment).

85 its use as a prognostic or predictive brain tumor marker are now warranted.

86 ns for tumor rebiopsy and use of circulating tumor markers are based on clinical experience and Panel

87 The currently available tumor markers are based on the antigen determination met

88 rthermore, the recent discovery of molecular tumor markers are expected to revolutionize the staging

89 Breast cancer tumor markers are frequently used among women with early

90 Better tumor markers are needed to enable the assignment of met

91 However, universal and highly specific tumor markers are unknown.

92 d colon cancers makes it a significant novel tumor marker as well as a potential therapeutic target.

93 The study examines the role inflammatory and tumor markers as biomarkers to preoperatively predict ou

94 luating the role of pretreatment circulating tumor markers as predictors of prognosis in chemotherapy

95 o assess cardiac surveillance algorithms and tumor markers as prognostic tools.

96 keratins are extensively used as diagnostic tumor markers, as epithelial malignancies largely mainta

97 tection of immunity to oncogenic proteins as tumor markers, as well as the development and testing of

98 ivation with VPA suppressed 2 neuroendocrine tumor markers, ASCL1 and chromogranin A.

99 he search was broadened by articles from the tumor marker ASCO panel literature search, as well as fr

100 al Oncology guidelines discourage the use of tumor marker assessment for routine surveillance in nonm

101 Of these, 16,653 (42%) received at least one tumor marker assessment, averaging 5.7 tests over 2 year

102 ding to sialyl-Tn (Neu5Acalpha2-6-GalNAc), a tumor marker associated with poor prognosis.

103 abilization of disease or decreases in serum tumor markers associated with stable disease in four pat

104 Hence it often fails to detect tumor markers at the early stages of cancer and other di

105 Radiographic or tumor marker-based screening detected six breast cancers

106 rvival was found in patients with increasing tumor markers before surgery compared with patients with

107 lin (MSLN) may be the most "dramatic" of the tumor markers, being strongly overexpressed in nearly on

108 CC) stages I-IV] were assessed for four mRNA tumor markers: beta-human chorionic gonadotropin (beta-h

109 Using mutated MYD88 as a tumor marker, BTK(Cys481) mutations were subclonal, with

110 Alpha-fetoprotein is the most widely used tumor marker, but has poor diagnostic accuracy and ethni

111 the smallest detectable concentration of the tumor marker CA 19-9 and Blue Tongue Viral antibody by o

112 jective tumor response, changes in the serum tumor marker CA 19-9, time to tumor progression (TTP), s

113 he treated patients experienced decreases in tumor marker (CA 19-9) levels of more than 50% from base

114 logic response criteria including changes in tumor marker CA125.

115 RECIST) complete or partial responses and/or tumor marker (CA125) responses, and three (6.0%) maintai

116 NSCLC tumor markers can be detected in histologically negative

117 to evaluate different methods by which serum tumor markers can be used to predict response independen

118 Tumor markers can facilitate understanding molecular cel

119 simultaneous determination of two different tumor markers, cancer antigen 153 (CA 15-3) and cancer a

120 phy scanning, magnetic resonance imaging, or tumor markers (carcinoembryonic antigen, CA 15-3, and CA

121 hy scans, magnetic resonance imaging, and/or tumor markers (carcinoembryonic antigen, CA 15-3, and CA

122 chest radiographs, hematologic blood counts, tumor markers (carcinoembryonic antigen, cancer antigen

123 ce to apoptosis, increased expression of the tumor marker cathepsin L, and a high degree of invasiven

124 function by recognizing the highly expressed tumor marker CD133, which is located on the surface of l

125 we observed that lymphocytes expressing the tumor marker CD30 increased in frequency weeks to months

126 ction of goat IgG and mouse IgG, and for the tumor markers CEA and AFP, were developed.

127 imaging, cyst fluid cytology, and cyst fluid tumor markers (CEA, CA 72-4, CA 125, CA 19-9, and CA 15-

128 Associations between baseline variables, tumor markers [CEA (carcinoembyronic antigen], CA125, CA

129 Tumor markers (chromogranin A and 5-hydroxyindoleacetic

130 alpha-Fetoprotein (AFP), a tumor marker currently used for the diagnosis and manage

131 MUC16/CA125 is a tumor marker currently used in clinics for the follow-up

132 Patients with slow serum tumor marker decline (alpha-fetoprotein and/or human cho

133 Serum tumor marker decline during chemotherapy was assessed pr

134 by means of objective radiologic response or tumor marker decline was observed in 9 of 11 evaluable p

135 Tumor markers decreased in the majority of patients, and

136 Receiver operator curve analysis of the tumor markers demonstrated that cyst fluid CEA (optimal

137 An assessment of SMAD7 genotypes with tumor markers did not reveal any significant differences

138 geno- and aptasensor for the detection of a tumor marker DNA and a low molecular weight analyte, ade

139 rapy regimens and mAbs directed against ATLL tumor markers do not alter this aggressive clinical cour

140 The study of tumor marker doubling times has guided the extent of sur

141 w reagents, when directed at the appropriate tumor markers (e.g. CD20 or Her-2), can control disease

142 The tumor marker eIF4E is overexpressed in 100% of larynx ca

143 se, two had metastatic disease, and four had tumor marker elevation only.

144 tion of affibodies or antibodies against the tumor markers epidermal growth factor receptor (EGFR) an

145 Because breast tumors are heterogeneous in tumor marker expression, we developed a "multimarker" re

146 As a tumor marker for colorectal cancers, carcinoembryonic an

147 ancer tissues, is considered as an important tumor marker for early cancer diagnostics.

148 6%, owing in part to the lack of a reliable tumor marker for early diagnosis.

149 ancers and currently is the best serum-based tumor marker for ovarian cancer.

150 CA 19-9 appears to be the best overall tumor marker for pancreatic cancer, and a subsequent ris

151 PSCA is a novel tumor marker for pancreatic carcinoma that has potential

152 eases in the prostate specific antigen (PSA) tumor marker for some patients.

153 CA 27.29 was also considered among the serum tumor markers for breast cancer.

154 Six tumor markers for colorectal cancer and eight for breast

155 ll prove useful for the identification of KS tumor markers for diagnosis and as potential drug target

156 Carbohydrate tumor-antigens are important tumor markers for diagnosis and functional characteristi

157 uring cancer progression, they may be useful tumor markers for diagnosis and prognosis.

158 are currently no routinely used circulating tumor markers for renal cancer, which is often detected

159 from individual LGL patients can be used as tumor markers for the malignant clone.

160 Multiple imputation was used to impute tumor markers for those missing data on 1-3 markers.

161 ity assessment and response correlation with tumor markers, functional imaging, and RET mutations.

162 us serve as both a diagnostic and prognostic tumor marker; furthermore, it may provide an effective t

163 evelopmental stage-specific silencing of the tumor marker gene alpha-fetoprotein (AFP).

164 y of HBx to modify p53 regulation of the HCC tumor marker gene, alpha-fetoprotein (AFP).

165 scription repression of an oncodevelopmental tumor marker gene.

166 ation of the hepatic alpha-fetoprotein (AFP) tumor marker gene.

167 Spiral computed tomography and serum tumor markers had low sensitivity in the detection of pa

168 Although no serological tumor marker has yet been shown to be sufficiently sensi

169 A vast number of tumor markers have been identified and rigorously evalua

170 g proteonomic genome analysis, new candidate tumor markers have been identified but await validation.

171 However, reliable diagnostic or prognostic tumor markers have not been identified for endometrial c

172 Serological tumor markers have proven valuable in the care of indivi

173 Different CRC subtypes, identified based on tumor markers, have been proposed to reflect these pathw

174 These tumor markers, however, are often prone to missing obser

175 The number of tumor markers identified has been exponentially increasi

176 Hematuria was the first tumor marker in a field that has grown to include solubl

177 In addition, the role of hCG as a tumor marker in a variety of cancers has also attracted

178 HER2 is a clinically important tumor marker in breast cancer; however, there is controv

179 ther solid tumors, and it has been used as a tumor marker in molecular detection strategies.

180 Fibrinogen is a potential tumor marker in pancreatic cancer.

181 CA 19-9 is an important tumor marker in patients with pancreatic adenocarcinoma.

182 in primary lung cancer and as a noninvasive tumor marker in plasma and/or serum DNA.

183 r determination of low levels of the VEGF165 tumor marker in serum samples.

184 ptamer at the electrode surface with VEGF165 tumor marker in the sample solution, which results in a

185 pear to have clinical utility as a surrogate tumor marker in the surveillance of TgAb-positive DTC pa

186 ach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed

187 g 10 different antibodies and five different tumor markers in a single 50 muL human serum sample.

188 preliminary profiling and identification of tumor markers in biological fluids in several cancer typ

189 e approach for the simultaneous detection of tumor markers in clinical samples.

190 he area of identifying potentially new serum tumor markers in germ cell tumor, as well as the role of

191 uggests that these mutations might be useful tumor markers in monitoring recurrence or minimal residu

192 The utility of serial monitoring of these tumor markers in patients with advanced disease is less

193 In addition, the expression of distinct tumor markers in PDGs was characterized by Muc5ac, S100P

194 Phi and %p2PSA may be useful as tumor markers in predicating patients harboring more agg

195 umor, as well as the role of the traditional tumor markers in predicting outcome to therapy is ongoin

196 This study evaluates a series of tumor markers in pretreatment biopsies from that trial T

197 strategy, the simultaneous detection of two tumor markers in single run carried out.

198 ent of GCTs as well, including the levels of tumor markers in the blood and cerebrospinal fluid that

199 Tumor markers in the serum and cerebrospinal fluid are e

200 es were detected by computed tomography scan/tumor-markers in 87%/3% of seminoma recurrences, in 48%/

201 We examined tumor markers, including PTGS2, phosphorylated AKT, KRAS

202 Analysis of tumor markers indicates that tumor biological difference

203 for performing multianalyte measurements of tumor markers is described.

204 The literature on tumor markers is plagued by nonpublication bias, selecti

205 As an easily accessible tumor marker, it could offer additional useful prognosti

206 The independent prognostic factors of serum tumor markers LDH and HCG, the sites of metastases, and

207 art due to the poor performance of available tumor markers leading to delays in diagnosis.

208 heterogeneity of risk factor associations by tumor marker levels while controlling for additional tum

209 postchemotherapy parameters, including serum tumor marker levels, radiology, and pathology at surgica

210 Tumor markers may improve the reliability of pathology e

211 rigenesis and the identification of specific tumor markers may lead to novel strategies for diagnosis

212 inflammatory markers in blood and serologic tumor markers may predict outcomes and are associated wi

213 inearly proportional to the concentration of tumor marker MDM2 in the wide dynamic range of 1pg/ml-1m

214 he preparation of variants of the epithelial tumor marker MUC1 carrying one or more Tn, T, or sialyl-

215 us by a either single genetic or biochemical tumor marker (MYCN, DNA, NSE, or ferritin), or by both u

216 nations (n = 30), increased plasma levels of tumor markers (n = 27), or clinical suspicion of recurre

217 on of NET (n = 70), elevated blood levels of tumor markers (n = 49), and image-based suspicion of NET

218 ble genes, including the recently discovered tumor marker NDRG1 (Cap43).

219 e have recently identified active Stat5 as a tumor marker of favorable prognosis in human breast canc

220 alpha-fetoprotein (AFP) gene is a diagnostic tumor marker of hepatocellular carcinoma.

221 etween AMP1 and its human homolog HsGCPII, a tumor marker of medical interest.

222 e potential as novel therapeutic targets and tumor markers of pancreatic cancer.

223 We also imaged different surface tumor markers on two live cell lines.

224 characterized them in order to uncover novel tumor markers, oncogenes, and therapeutic targets for HC

225 d imply the potential of AP-2beta as a novel tumor marker or a cancer therapeutic target.

226 ed genes, seven showed potential as possible tumor markers or antigens as determined by further expre

227 commonly occurring cancers, other candidate tumor markers or antigens could be located and evaluated

228 We found no association between serum tumor markers or ERCC1 expression with response or survi

229 nded surveillance regimens using ultrasound, tumor markers or testicular biopsy are too costly and do

230 ctive targets for novel therapeutic targets, tumor markers, or as a means of screening pancreatic can

231 as age, cyst location, mural nodules, serum tumor markers, or bilirubin.

232 e than 2 cm, multiple masses, elevated serum tumor markers, or disease outside the primary landing zo

233 due to clinical symptoms, elevated levels of tumor markers, or indeterminate tumors suggestive of NET

234 ith patients with normal and declining serum tumor markers (P =.09).

235 s compared with patients with elevated serum tumor markers (P =.33).

236 actor Receptor 2 (HER2), as a key prognostic tumor marker, plays a critical role in screening, early

237 univariate analysis, all 3 inflammatory and tumor markers predicted for both PFS and OS, respectivel

238 resis' technologies to facilitate tissue and tumor-marker profiling under these circumstances.

239 Reporting recommendations for tumor marker prognostic studies criteria were followed,

240 The REMARK (Reporting Recommendations for Tumor Marker Prognostic Studies) guideline includes a ch

241 ns and REMARK [Reporting Recommendations for Tumor Marker Prognostic Studies] criteria for reporting

242 The tumor marker (PSMA) has been detected in a range of conc

243 ossible that serum IGF-I may be serving as a tumor marker rather than an etiologic factor in prostate

244 The field of bladder cancer tumor markers remains a rapidly evolving area in which n

245 31% expressed 4, 3, 2, 1, and 0 of the mRNA tumor markers, respectively.

246 rdized multivariate analysis procedures, new tumor markers should be carefully examined for their bio

247 Tumor markers should not be the sole criteria for determ

248 There is an urgent need to identify relevant tumor markers showing high sensitivity and specificity f

249 cancer immunotherapeutics with no need for a tumor marker.Significance: Targeted type I interferon el

250 lusion of quality-of-life data and molecular tumor markers, so that this information could be capture

251 ersistent postorchiectomy elevation of serum tumor markers (STM) or clinical stage (CS) IIB disease f

252 to develop a score based primarily on serum tumor markers (STMs) that could predict short cancer-spe

253 At diagnosis, 43 patients had elevated serum tumor markers (STMs), and 20 had extramediastinal diseas

254 istology, hematological status, serial serum tumor markers (STMs), and STM changes over time.

255 treme use of disease-monitoring tests (serum tumor markers [STMs] and radiographic imaging) among wom

256 er when designing, conducting, and analyzing tumor marker studies and prognostic studies in medicine

257 adherence to higher standards for reporting tumor marker studies.

258 matic reviews and meta-analyses of published tumor marker studies.

259 matic reviews and meta-analyses of published tumor marker studies.

260 ms are discussed, including development of a tumor marker study registry, greater attention to assay

261 e with serial physical examination and serum tumor markers such as estradiol and inhibin is reasonabl

262 New tumor markers, such as lactate dehydrogenase isoenzyme-1

263 notypically altered in that they express the tumor marker survivin.

264 t express pRb and express the neuroendocrine tumor markers synaptophysin and microtubule-associated p

265 tigen profiling of intact tumors to identify tumor markers targetable with antibodies.

266 ial benefits and harms of surveillance-based tumor marker testing is needed.

267 To update the recommendations for the use of tumor marker tests in the prevention, screening, treatme

268 Our objective was to determine use of tumor marker tests such as carcinoembryonic antigen and

269 ived no abdominal imaging, chest imaging, or tumor marker tests within the first year of diagnosis.

270 Alpha-fetoprotein is a tumor marker that has been used for surveillance and dia

271 Carcinoembryonic antigen (CEA) is a tumor marker that is associated with metastasis, poor re

272 mbrane antigen, a well-known prostate cancer tumor marker that is overexpressed on prostate acinar ep

273 Development of tumor markers that can detect colon cancer at an early s

274 A new class of tumor markers that recognize cytokeratins, which compris

275 ethod has been tested for the detection of a tumor marker, the Prostate Specific Membrane Antigen (PS

276 ase detection of alpha-fetoprotein, a common tumor marker, the system shows a greater than 200-fold s

277 (5%) achieved a partial response with normal tumor markers; therefore, 23 (62%) achieved a favorable

278 To date, well-characterized molecular tumor markers to detect occult breast cancer cells in bl

279 Currently, there are no specific tumor markers to determine initial risk or progression t

280 variables could be combined with biological tumor markers to provide a novel means of determining pr

281 ied into 5 subtypes based on combinations of tumor markers: type 1 (microsatellite instability [MSI]-

282 y-stage breast cancer between 2001 and 2007, tumor marker usage within 2 years after diagnosis was id

283 CA 125 is the standard tumor marker used to follow women during or after treatm

284 for monoclonal immunoglobulin as a leukemia tumor marker using a surface plasmon resonance (SPR) bio

285 igen and was capable of measuring a specific tumor marker using electrochemical enzyme-based competit

286 Testing for the NMP22 tumor marker was conducted in a blinded manner.

287 C if a prolonged clearance of elevated serum tumor markers was observed after two cycles of the cispl

288 lex detection of three different lung cancer tumor markers was realized.

289 Prechemotherapy levels of serum tumor markers were alpha-fetoprotein (AFP) 2.0 ng/mL, hu

290 d CONCLUSIONS: Thirteen categories of breast tumor markers were considered, six of which were new for

291 None of the tumor markers were expressed in any normal donor bloods.

292 d pathologic staging parameters and biologic tumor markers were investigated to devise the scoring sy

293 heterogeneity of risk factors with specific tumor markers when using standard competing-risk surviva

294 eriodically by quantifying serum levels of a tumor marker), whereas tumors grew progressively in mice

295 sk factor associations according to specific tumor markers while controlling for other markers.

296 results suggest that FAIM2 is a potential NE tumor marker with higher expression in atypical carcinoi

297 Sixty-one candidate tumor markers with expression predicted to be characteri

298 powerful tools for screening and identifying tumor markers with only minute samples.

299 on human prostatic acid phosphatase (PAP), a tumor marker, with a limit of detection of 11 pM and C-r

300 id to the expression pattern and location of tumor markers within the biopsy specimen as these parame